Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will fund the research and development expenses, to advance its preclinical B7-H6 specific CAR T-cell candidates, to discover and develop additional preclinical product candidates using its proprietary non-gene edited short hairpin RNA technology platform.
Lead Product(s): B7-H6 Specific CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fortress Investment Group
Deal Size: $10.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 24, 2023